Sign up for the Abwiz Bio Newsletter to get actionable advice and exclusive deals direct to your inbox.
Kv1.3 (26B-R4-D9) rabbit mAb
20 μL is enough antibody for at least 20 Western blots.
The voltage-dependent postassium ion channel (Kv) is a classical Shaker-type membrane assicated integral protein with six transmembrane segments (1). Kv1.3 belongs to a large and very diverse family, consisting of multiple subfamilies (Kv1-4). Kv plays an imprtant role in the physiological and pathophysiological processes of excitation and non-excitation cells. Kv channels were first discovered in non-excitable cessl, T-lymphocytes (2). Kv1.3 are expressed in quite diverse cell types including human T and B lymphocytes, macrophages, platelets, fibroblasts, osteoclasts, microglia, oligodendrocytes, brain (e.g., olfactory bulb, hippocampus, and cerebral cortex), lung islets, thymus, spleen, lymph nodes, and testis (3). In addition to the expression of Kv1.3 in the cell membrane, they are also expressed in the inner mitochondrial membrane (mito Kv1.3) of normal T lymphocytes and cancer cells (4).
Kv1.3 channels are selectively permeable for potassium ions and are activated upon a change of cell membrane voltage. Activation of these membrane embedded proteins facilitate transportation of potassium ions across cell membrane down their electrochemical gradients. Kv channels are involved in regulating calcium signaling, cell volume regulation, cytokines secretion, cell proliferation and migration.
The channel activity is inhibited by many chemically unrelated compounds: heavy-metal cations, small-molecule organic compounds and venom-isolated oligopeptides (3, 5). The most potent specific inhibitors inhibit the channel at sub nanomolar concentrations (7). Inhibition of Kv1.3 channel by specific inhibitors may be beneficial in therapy of T-lymphocyte-mediated autoimmune diseases (e.g., sclerosis multiplex, type I diabetes mellitus, rheumatoid arthritis, psoriasis), chronic renal failure, asthma, obesity, type II diabetes mellitus, cognitive disabilities, and some cancer disorders (7).
|Cross Reactivity||Predicted to work with mouse, rat and other homologues.|
|Formulation||1X PBS, 0.09% NaN3, 0.2% BSA|
|Recommended Usage||For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells or 5 µL per 100 µL of staining volume. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.|
|Pseudonyms||Potassium voltage-gated channel subfamily A member 3, Kv1.3, KCNA3, HGK5|
|References||1. Wulff H, Zhorov BS, (2008). Chem. Rev. 108:1744–1773.
2. Chiang EY, et al., (2017) Nat. Commun. 8:14644. 10.1038/ncomms14644
3. Gutman G, et al. (2005) Pharmacol Rev (2005) 67:473–508.
4. Szabo I, et al.. (2005) J Biol Chem. (2005) 280:12790–12798.
5. Panyi G, et al., (2006) Curr Pharm Des. 12:2199–220.
6. Serrano-Albarras A, et a., (2018) Exp Opin Therapeut Targets. 22:101–105.
7. Teisseyre A, et al., (2015) Adv Clin Exp Med. 24:517–524.